Lifetime Risk of Breast Cancer in BRCA2 Carriers
Women with pathogenic BRCA2 variants face a lifetime breast cancer risk of approximately 69% by age 80 years, with family history significantly modifying this risk upward to as high as 86% in those with multiple affected first-degree relatives.
Risk Estimates from Prospective Data
The most robust prospective data comes from large international cohort studies that followed BRCA2 carriers over time:
- Cumulative breast cancer risk by age 80: 69% (95% CI, 61%-77%) 1
- Risk modified by family history: Women with ≥2 affected first- or second-degree relatives have nearly double the risk (HR 1.91) compared to those without family history 1
- Recent population-based data: Confirms 66.1% (95% CI, 57.5%-72.9%) lifetime risk, increasing to 86.3% in carriers with ≥2 affected first-degree relatives 2
Age-Specific Risk Pattern
BRCA2 carriers show a distinct temporal pattern that differs from BRCA1:
- Breast cancer incidence increases rapidly from early adulthood through ages 40-50 years
- After age 50, incidence plateaus at a constant rate of 20-30 cases per 1,000 person-years through age 80 1
- Significant risk persists in the seventh decade: A 24.2% increase in cumulative incidence occurs between ages 60-70 3
This sustained late-life risk has critical implications—intensive screening and risk-reduction strategies remain justified even after age 60, contrary to assumptions that risk diminishes with age.
Contralateral Breast Cancer Risk
For BRCA2 carriers diagnosed with breast cancer:
- 20-year cumulative risk of contralateral breast cancer: 26% (95% CI, 20%-33%) 1
- 10-year risk: 29.2% (95% CI, 22.9%-35.5%) 3
- Risk increases approximately 3% per year 3
This substantially elevated contralateral risk should inform discussions about bilateral versus unilateral mastectomy at initial diagnosis.
Mutation Location Matters
Breast cancer risk is nearly twice as high for mutations located outside the central region (positions c.2831-c.6401) compared to mutations within this region (HR 1.93,95% CI 1.36-2.74) 1. This finding suggests that mutation location should be incorporated into individualized risk assessment when available.
Clinical Context and Screening Implications
The NCCN guidelines emphasize that screening should begin at age 25 with annual breast MRI (preferred) or mammography, transitioning to combined annual mammography plus MRI from ages 30-75 4. The age to begin screening can be individualized if family history includes breast cancer diagnosis before age 30.
Risk-reducing bilateral mastectomy reduces breast cancer incidence by approximately 90% 5 and should be discussed as an option, particularly for BRCA2 carriers with strong family history. However, the timing is typically recommended between ages 40-45 for BRCA2 carriers (later than the 35-40 recommendation for BRCA1) given the later age of onset 4.
Important Caveats
- 30-40% of BRCA2 carriers will NOT develop breast cancer despite their elevated risk 6
- Predicting the exact age of cancer onset for individual carriers remains impossible
- Most BRCA2-associated breast cancers (up to 80%) are hormone receptor-positive, unlike BRCA1-associated cancers which are predominantly triple-negative 6, 7
- This hormone receptor profile makes BRCA2 carriers potentially responsive to chemoprevention with tamoxifen, which showed a 62% risk reduction in one analysis 4
The combination of high lifetime risk, sustained risk at older ages, and substantial contralateral breast cancer risk underscores the importance of intensive surveillance and consideration of risk-reducing strategies for BRCA2 carriers throughout their lifespan.